{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T20:38:17Z","timestamp":1768595897688,"version":"3.49.0"},"reference-count":29,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ra Pharmaceuticals"},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Catalyst"},{"name":"Orphazyme"},{"name":"Alnylum"},{"name":"Argenx"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Autoimmune myasthenia gravis (MG) is a neuromuscular junction disorder marked clinically by fatigable muscle weakness and serologically by the presence of autoantibodies against acetylcholine receptors (AChRs), muscle-specific kinase (MuSK), or lipoprotein-related protein 4 (LPR4). Over the past few decades, the mortality of patients with MG has seen a dramatic decline secondary to evolving interventions in critical care and medical management. In the past 2 to 3 years, there have been several changes in standard of care for the treatment of MG. These changes include confirmation of the benefit of thymectomy versus medical management alone in AChR patients and a new US Food and Drug Administration-approved medication for refractory MG. There are also several exciting new prospective drugs in the pipeline, which are in different stages of clinical trial testing.<\/ns4:p>","DOI":"10.12688\/f1000research.15973.1","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T12:00:31Z","timestamp":1540987231000},"page":"1727","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Recent advances in understanding and managing myasthenia gravis"],"prefix":"10.12688","volume":"7","author":[{"given":"Allison","family":"Jordan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8282-764X","authenticated-orcid":false,"given":"Miriam","family":"Freimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"1023-36","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies.","volume":"14","author":"N Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"264-70","DOI":"10.1016\/j.neuroscience.2018.01.042","article-title":"Introducing Autoimmunity at the Synapse by a Novel Animal Model of Experimental Autoimmune Myasthenia Gravis.","volume":"374","author":"J Wang","year":"2018","journal-title":"Neuroscience."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"918-23","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4.","volume":"12","author":"J Verschuuren","year":"2013","journal-title":"Autoimmun Rev."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"3422-6","DOI":"10.1073\/pnas.75.7.3422","article-title":"Effect of myasthenic patients' immunoglobulin on acetylcholine receptor turnover: selectivity of degradation process.","volume":"75","author":"D Drachman","year":"1978","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"278-86","DOI":"10.1111\/j.1365-2249.2006.03198.x","article-title":"Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats.","volume":"146","author":"J Chamberlain-Banoub","year":"2006","journal-title":"Clin Exp Immunol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"326-32","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis.","volume":"505","author":"A Engel","year":"1987","journal-title":"Ann N Y Acad Sci."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"294-302","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice.","volume":"146","author":"B Morgan","year":"2006","journal-title":"Clin Exp Immunol."},{"key":"ref-8","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms [version 1; referees: 2 approved].","volume":"5","author":"W Phillips","year":"2016","journal-title":"F1000Res."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"1025-8","DOI":"10.1084\/jem.173.4.1025","article-title":"The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain.","volume":"173","author":"M Tao","year":"1991","journal-title":"J Exp Med."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"159-88","DOI":"10.1146\/annurev-physiol-022516-034255","article-title":"Neuromuscular Junction Formation, Aging, and Disorders.","volume":"80","author":"L Li","year":"2018","journal-title":"Annu Rev Physiol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"253-60","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology.","volume":"36","author":"M Hehir","year":"2018","journal-title":"Neurol Clin."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"363-6","DOI":"10.1002\/mus.22327","article-title":"Estimated cost of treating myasthenia gravis in an insured U.S. population.","volume":"45","author":"J Guptill","year":"2012","journal-title":"Muscle Nerve."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"141-9","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis.","volume":"37","author":"D Grob","year":"2008","journal-title":"Muscle Nerve."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"837-41","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.","volume":"68","author":"L Zinman","year":"2007","journal-title":"Neurology."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"400-6","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.","volume":"71","author":"D Sanders","year":"2008","journal-title":"Neurology."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"494-9","DOI":"10.1196\/annals.1254.064","article-title":"Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study.","volume":"998","author":"M Meriggioli","year":"2003","journal-title":"Ann N Y Acad Sci."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"57-64","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.","volume":"87","author":"M Pasnoor","year":"2016","journal-title":"Neurology."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"511-22","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized Trial of Thymectomy in Myasthenia Gravis.","volume":"375","author":"G Wolfe","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"678-90","DOI":"10.1111\/j.1749-6632.1981.tb33766.x","article-title":"Observations of the natural history of myasthenia gravis and the effect of thymectomy.","volume":"377","author":"H Oosterhuis","year":"1981","journal-title":"Ann N Y Acad Sci."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"976-86","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.","volume":"16","author":"J Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"419-25","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary.","volume":"87","author":"D Sanders","year":"2016","journal-title":"Neurology."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"552-5","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up.","volume":"3","author":"D Anderson","year":"2016","journal-title":"Ann Clin Transl Neurol."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"452-5","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: Extended prospective study results.","volume":"58","author":"G Beecher","year":"2018","journal-title":"Muscle Nerve."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"259-66","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study.","volume":"4","author":"R Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"1069-77","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.","volume":"89","author":"M Hehir","year":"2017","journal-title":"Neurology."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"e2182-e2194","DOI":"10.1212\/WNL.0000000000005692","article-title":"2018 Emerging Science Abstracts.","volume":"90","year":"2018","journal-title":"Neurology."},{"key":"ref-27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study.","volume":"9","author":"P Kiessling","year":"2017","journal-title":"Sci Transl Med."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"699-700","DOI":"10.1212\/01.wnl.0000267884.39468.7a","article-title":"Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase.","volume":"69","author":"Z Argov","year":"2007","journal-title":"Neurology."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"13-6","DOI":"10.1111\/j.1749-6632.2012.06825.x","article-title":"Further developments with antisense treatment for myasthenia gravis.","volume":"1275","author":"J Sussman","year":"2012","journal-title":"Ann N Y Acad Sci."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/7-1727\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1727\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1727\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T12:16:46Z","timestamp":1553861806000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/7-1727\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":29,"URL":"https:\/\/doi.org\/10.12688\/f1000research.15973.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.17445.r39809","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.17445.r39807","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.17445.r39808","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/7-1727\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.17445.r39808, Lin Mei, Department of Neuroscience, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA, 31 Oct 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1727\/v1#referee-response-39808","order":0,"name":"referee-response-39808","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.17445.r39809, Jon Lindstrom, Medical School of the University of Pennsylvania , Philadelphia, Pennsylvania, USA, 31 Oct 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1727\/v1#referee-response-39809","order":1,"name":"referee-response-39809","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.17445.r39807, Nicholas J. Silvestri, University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, New York, USA, 31 Oct 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1727\/v1#referee-response-39807","order":2,"name":"referee-response-39807","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"Miriam L. Freimer has previously received research funding from Ra Pharmaceuticals, Alexion Pharmaceuticals, UCB, Argenx, Alnylum, Catalyst and Orphazyme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}